HUP0105491A3 - Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension - Google Patents

Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension

Info

Publication number
HUP0105491A3
HUP0105491A3 HU0105491A HUP0105491A HUP0105491A3 HU P0105491 A3 HUP0105491 A3 HU P0105491A3 HU 0105491 A HU0105491 A HU 0105491A HU P0105491 A HUP0105491 A HU P0105491A HU P0105491 A3 HUP0105491 A3 HU P0105491A3
Authority
HU
Hungary
Prior art keywords
cyclopentanecarboxamido
azepine
benz
carboxyethyl
tetrahydro
Prior art date
Application number
HU0105491A
Other languages
English (en)
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of HUP0105491A2 publication Critical patent/HUP0105491A2/hu
Publication of HUP0105491A3 publication Critical patent/HUP0105491A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0105491A 1999-02-16 2000-02-10 Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension HUP0105491A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19906310A DE19906310A1 (de) 1999-02-16 1999-02-16 Arzneimittel zur Behandlung von Bluthochdruck

Publications (2)

Publication Number Publication Date
HUP0105491A2 HUP0105491A2 (en) 2002-06-29
HUP0105491A3 true HUP0105491A3 (en) 2002-08-28

Family

ID=7897580

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105491A HUP0105491A3 (en) 1999-02-16 2000-02-10 Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension

Country Status (28)

Country Link
US (1) US6482820B2 (hu)
EP (1) EP1154777B1 (hu)
JP (1) JP2002537258A (hu)
KR (2) KR20010101922A (hu)
CN (1) CN1198619C (hu)
AR (1) AR036864A1 (hu)
AT (1) ATE295174T1 (hu)
AU (1) AU773240C (hu)
BR (1) BR0008260A (hu)
CA (1) CA2362273C (hu)
CZ (1) CZ301499B6 (hu)
DE (2) DE19906310A1 (hu)
DZ (1) DZ3014A1 (hu)
ES (1) ES2238268T3 (hu)
HK (1) HK1042247B (hu)
HU (1) HUP0105491A3 (hu)
IL (1) IL144622A (hu)
NO (1) NO329588B1 (hu)
NZ (1) NZ514058A (hu)
PL (1) PL195283B1 (hu)
PT (1) PT1154777E (hu)
RU (1) RU2270679C2 (hu)
SK (1) SK287254B6 (hu)
TR (1) TR200102386T2 (hu)
TW (1) TWI221770B (hu)
UA (1) UA63032C2 (hu)
WO (1) WO2000048601A1 (hu)
ZA (1) ZA200105828B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
DE60040089D1 (de) * 1999-11-19 2008-10-09 Solvay Pharm Bv Menschliches homolog aus der familie der metalloproteasen
CA2357833C (en) * 2000-10-04 2005-11-15 Warner-Lambert Company Treatment of pulmonary hypertension using vasopressin antagonist
CA2447598A1 (en) * 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
EP1448567B1 (en) * 2001-09-10 2009-12-30 Tibotec Pharmaceuticals Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
KR100979077B1 (ko) 2002-01-16 2010-08-31 솔베이 파마슈티칼스 비. 브이 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
AU2004290925B2 (en) * 2003-11-18 2010-07-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
CA2714272C (en) * 2008-01-31 2016-06-28 Vanderbilt University Therapeutic treatment for lung conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel

Also Published As

Publication number Publication date
US20020052361A1 (en) 2002-05-02
TR200102386T2 (tr) 2002-01-21
CN1198619C (zh) 2005-04-27
CZ301499B6 (cs) 2010-03-24
HK1042247A1 (en) 2002-08-09
UA63032C2 (en) 2004-01-15
KR20070027719A (ko) 2007-03-09
KR100797665B1 (ko) 2008-01-23
DE19906310A1 (de) 2000-08-17
PL195283B1 (pl) 2007-08-31
ES2238268T3 (es) 2005-09-01
WO2000048601A1 (de) 2000-08-24
TWI221770B (en) 2004-10-11
NO20013958L (no) 2001-10-15
AU2547600A (en) 2000-09-04
AU773240C (en) 2004-11-18
ZA200105828B (en) 2002-07-15
CA2362273C (en) 2010-05-25
CZ20012672A3 (cs) 2002-02-13
RU2270679C2 (ru) 2006-02-27
ATE295174T1 (de) 2005-05-15
JP2002537258A (ja) 2002-11-05
US6482820B2 (en) 2002-11-19
IL144622A (en) 2006-08-20
AR036864A1 (es) 2004-10-13
HK1042247B (zh) 2005-09-23
NO329588B1 (no) 2010-11-15
EP1154777A1 (de) 2001-11-21
PL350167A1 (en) 2002-11-18
CA2362273A1 (en) 2000-08-24
DZ3014A1 (fr) 2004-03-27
NZ514058A (en) 2001-09-28
AU773240B2 (en) 2004-05-20
KR20010101922A (ko) 2001-11-15
BR0008260A (pt) 2001-11-06
DE50010284D1 (de) 2005-06-16
CN1339966A (zh) 2002-03-13
SK10822001A3 (sk) 2002-03-05
NO20013958D0 (no) 2001-08-15
EP1154777B1 (de) 2005-05-11
SK287254B6 (sk) 2010-04-07
PT1154777E (pt) 2005-07-29
HUP0105491A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
HUP0105491A2 (en) Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension
AU2001263399A1 (en) 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indo linone derivatives
HK1044537A1 (en) 1,4-benzothiazepine derivatives methods for the production thereof, medicaments containing these compounds and the use
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
PL343726A1 (en) 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
HUP0104964A3 (en) Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing the compounds
HUP0200556A3 (en) Medicament for treating diabetes
IL146117A0 (en) New pharmaceutically active compounds
HK1046405A1 (zh) 作為nmda受體拮抗劑用於治療疼痛的取代的1，5-二氫吡咯-2-酮衍生物
MXPA00012647A (es) Derivados n-sustituidos de acido 5-oxiiminobarbiturico.
SI0988302T1 (en) Benzonaphthyridines
HUP9801950A3 (en) 2-(arylphenyl-amino)-imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0204360A3 (en) Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament and medicaments containing said compounds
HK1066219A1 (en) 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors
AU6043600A (en) Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications
PL344994A1 (en) Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems
HK1061843A1 (en) Process for cis-1-(2-(4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronape ethyl) pyrrolidine
IL142581A (en) Medicament for treating heart disease
HUP0104029A3 (en) New crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide and medicaments containing them
IL155706A0 (en) Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole
MX252778B (es) Modificacion cristalina ii de la 2-[2 -(1-cloro- ciclopropil)- 3-(2-clorofenil)- 2 hidroxi- propil]-2, 4-dihidro -3h-1, 2, 4-triazol -3-tiona.
IL129647A0 (en) Substituted 4-(6-fluoro-(1H)-indol-3-YL)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
ZA200007205B (en) A process for the manufacture of the salts of sulfonylaminocarbonyl triazolinones.
HU0005004D0 (en) Process for the manufacture of sulfonylaminocarbonyl triazolinone salts
HUP0200187A3 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees